▲ Peaking
Business
🔮 fades
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
AbbVie’s $10.9B bid for Apogee Therapeutics signals a high-stakes bet on next-gen autoimmune treatments—including a rival to Dupixent.